SCHEMBL2030131

SCHEMBL2030131

CC(C)[C@H](O)[C@@H](N)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.65
USP2 O75604 1/20 0.50
SLCO1B1 Q9Y6L6 1/20 0.50
TP53 P04637 1/20 0.45
SLC1A3 P43003 2/20 0.42
SLC1A2 P43004 2/20 0.42
SLC1A1 P43005 2/20 0.42
PTGS1 P23219 2/20 0.36
NR1I2 O75469 1/20 0.36
ADRA1A P35348 1/20 0.36
LMNA P02545 1/20 0.36
BLM P54132 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ACHE P22303 1/20 0.36
LTA4H P09960 1/20 0.34
GABRP O00591 2/20 0.33
GABRD O14764 2/20 0.33
GABRA1 P14867 2/20 0.33
GABRB1 P18505 2/20 0.33
GABRG2 P18507 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2032146 1.00 SLC7A5 (0.65) SLC7A5USP2SLCO1B1TP53SLC1A3
SCHEMBL587006 1.00 SLC7A5 (0.65) SLC7A5USP2SLCO1B1TP53SLC1A3
SCHEMBL200720 1.00 SLC7A5 (0.65) SLC7A5USP2SLCO1B1TP53SLC1A3
SCHEMBL497774 1.00 SLC7A5 (0.65) SLC7A5USP2SLCO1B1TP53SLC1A3
SCHEMBL200721 1.00 SLC7A5 (0.65) SLC7A5USP2SLCO1B1TP53SLC1A3
SCHEMBL1253160 1.00 SLC7A5 (0.65) SLC7A5USP2SLCO1B1TP53SLC1A3
SCHEMBL15883792 0.84 SLC7A5 (0.59) SLC7A5USP2SLCO1B1TP53SLC1A3
SCHEMBL2405354 0.84 SLC7A5 (0.59) SLC7A5USP2SLCO1B1TP53SLC1A3
SCHEMBL1512910 0.81 SLC7A5 (0.55) SLC7A5USP2SLCO1B1TP53SLC1A3
SCHEMBL1512907 0.81 SLC7A5 (0.55) SLC7A5USP2SLCO1B1TP53SLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10633630-B2 Acceleration of Mycobacterium growth ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) 2020-04-28 US disclosed
EP-3158053-B1 ACCELERATION OF MYCOBACTERIUM GROWTH ST GEORGES HOSPITAL MEDICAL SCHOOL (GB) 2019-03-13 EP disclosed
US-9707282-B2 Small cationic antimicrobial peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2017-07-18 US disclosed
US-20170121672-A1 ACCELERATION OF MYCOBACTERIUM GROWTH ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) 2017-05-04 US disclosed
EP-3158053-A1 ACCELERATION OF MYCOBACTERIUM GROWTH St. George's Hospital Medical School (GB) 2017-04-26 EP disclosed
EP-2782567-B1 DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) UNIV CALIFORNIA (US) 2017-03-22 EP disclosed
US-20160235707-A1 DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) FOND ST ITALIANO TECNOLOGIA (IT) 2016-08-18 US disclosed
US-9353075-B2 Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-05-31 US disclosed
EP-2069303-B1 ANTIVIRAL PROTEASE INHIBITORS GILEAD SCIENCES INC (US) 2016-03-30 EP disclosed
WO-2015193688-A1 ACCELERATION OF MYCOBACTERIUM GROWTH ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) 2015-12-23 WO disclosed
US-7371875-B2 Cytotoxic agents and methods of use MIIKANA THERAPEUTICS, INC. (US) 2008-05-13 US disclosed
WO-2008022444-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-02-28 WO disclosed
WO-2008011117-A2 ANTIVIRAL PROTEASE INHIBITORS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed
US-7144899-B2 Thrombin inhibitors MERCK & CO., INC. (US) 2006-12-05 US disclosed
US-20050203162-A1 Cytotoxic agents and methods of use MIIKANA THERAPEUTICS CORPORATION 2005-09-15 US disclosed
US-20040073025-A1 Thrombin inhibitors MERCK SHARP & DOHME CORP. 2004-04-15 US disclosed
US-20030199571-A1 (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives SMITHKLINE BEECHAM P.L.C. (GB) 2003-10-23 US disclosed
EP-1244616-A1 (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES SmithKline Beecham plc (GB) 2002-10-02 EP disclosed
WO-2002064559-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-08-22 WO disclosed
WO-2001047874-A1 (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES SMITHKLINE BEECHAM P.L.C. (GB) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203162-A1 Cytotoxic agents and methods of use XIAP, RIOX2, PSMA6 SLC7A5 4209/4885USP2 209/4885SLCO1B1 4137/4885
US-20030199571-A1 (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives CD40, CD22, CD2 SLC7A5 939/4885USP2 4149/4885SLCO1B1 1033/4885
US-20160235707-A1 DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) NAAA, FAAH, FAAH2 SLC7A5 3854/4885USP2 908/4885SLCO1B1 2905/4885
US-20040073025-A1 Thrombin inhibitors F2, F11, F10 SLC7A5 4181/4885USP2 1023/4885SLCO1B1 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.